-
For some patients, enrolling in a clinical trial is not an option. They may meet exclusion criteria, or the nearest trial center may be geographically inaccessible, despite having a disease or condition that could benefit from investigational treatment. In such cases, the patients physician can request expanded individual patient access from the Food and Drug Administration. In dire situations, the physician can seek emergency use.
-
IRBs working with community partners on non-medical studies need fresh tools, such as resourcefulness and imagination, when engaging in training and education.
-
-
-
The fda has approved the first naloxone hand-held auto-injector. It is intended for family members or caregivers to treat suspected opioid overdose. The auto-injector can be carried in a pocket or stored in a medicine cabinet. The product was reviewed under the agencys priority review program. It is marketed by Kaleo, Inc. as Evzio.
-
Bendopnea, which is defined as shortness of breath when bending over, has been found to be a dominant symptom in patients with heart failure. It appears to be caused by a further increase in filling pressures when bending over in patients with heart failure, especially when filling pressures are already high and the cardiac index is reduced.
-
In a study of veterans with no recent history of depression or opioid use, the risk of developing depression increased as the duration of opioid analgesic exposure increased.
-
The authors concluded that vitamin D supplementation in patients with fibromyalgia syndrome (FMS) and low levels of vitamin D might be an economical, safe, and effective therapy for patients with FMS.
-
-
Complying with the Emergency Treatment and Labor Act (EMTALA) can be hard enough before court rulings give the rule a longer reach. Courts in Kentucky, Ohio, Michigan, and Tennessee have passed laws that make EMTALA applicable even after admission.
